LCM
PLRX icon

Lynx1 Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Lynx1 Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.05M Buy
+1,798,070
New +$2.19M 0.24% 12

Other funds holding PLRX

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Lynx1 Capital Management's PLRX Position: Q2 2026 in Review

Lynx1 Capital Management opened a new position in Pliant Therapeutics (PLRX) in Q2 2026: 1,798,070 shares worth $2.05M. The stake represents 0.24% of the portfolio and ranks #12 among its holdings.

63 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Lynx1 Capital Management held 1,798,070 shares of Pliant Therapeutics worth $2.05M as of Q2 2026.
  • Pliant Therapeutics was a new Lynx1 Capital Management position in Q2 2026.
  • Pliant Therapeutics made up 0.24% of Lynx1 Capital Management's portfolio in Q2 2026, its #12 holding.
  • 63 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.